OUR PLATFORMS

Pioneering Spirit
& Ambition

QurAlis is breaking through the barriers of science in our quest to bring much-needed precision therapies to patients.

QR43™: Proprietary & Investigative TDP-43 Platform

FlexASO™: Proprietary Anti-Sense Oligonucleotide Splice Modulator Platform

Team

Pipeline

Culture

Patients

November 29, 2023

QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia

November 20, 2023

QurAlis to Present at the Piper Sandler 35th Annual Healthcare Conference

September 6, 2023

QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases

July 11, 2023

QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS